Interview with acting CEO Johan Giléus about the Q1 report 2022
Capital Markets Day 2022
InDex Pharmaceuticals would like to raise the awareness of World IBD Day by wearing the Purple Ribbon, an international symbol of inflammatory bowel disease (IBD).
Our mission is to significantly improve
the lives of patients suffering from
immunological disorders by providing
effective and safe drugs for diseases
with high unmet medical needs.
-
InDex Pharmaceuticals announces successful interactions with the PMDA for the clinical development of cobitolimod in Japan
August 16, 2022 Non Regulatory
-
InDex Pharmaceuticals gets new patent for cobitolimod granted in Europe
July 13, 2022 Regulatory
InDex Pharmaceuticals Holding AB (publ) published its interim report Q1 for January-March 2022 on May 16, 2021 at 08:00 a.m. CEST.
-
Interim Report Q2 2022
-
Presentation at Pareto Securities Healthcare Conference
-
Interim Report Q3 2022
Our phase III study CONCLUDE
Have a look at InDex’s corporate presentation
InDex Pharmaceuticals is developing cobitolimod for treatment of moderate to severe left-sided ulcerative colitis
Proud partner of:
